Breaking News on Global Pharmaceutical Technology & Manufacturing

Micro Labs completes repeat studies and predicts drugs will be back on the market in autumn

Sandoz repeats tests and Teva pulls malaria pill as EMA calls for suspension of Semler trialled drugs

25-Jul-2016 - Sandoz is repeating bioequivalence studies and Teva is withdrawing an antimalarial after the EMA recommended that drugs trialled by Semler Research Centre should be suspended.

EMA proposes changes to Ph I guidelines after fatal BIA 10-2474 trial

21-Jul-2016 - European authorities want to revise the guidelines covering first-in-human studies in light of the French trial in which one man died and others were hospitalised earlier this year.

GSK to expand recall of antibiotics made at Worthing API unit

21-Jul-2016 - GSK will recall more antibiotics made at a UK API unit that has been offline since the US FDA raised contamination concerns last year.

Update: Sandoz remains committed to launching 5 biosims by 2020

US FDA rejects Sandoz’s Neulasta biosimilar

19-Jul-2016 - The US FDA has issued Sandoz with a complete response letter for its Neulasta biosimilar.

Report: Congress needs to update human research regulations

19-Jul-2016 - Ethical principles for conducting research involving humans were originally detailed in 1978 – today, a new report is urging Congress to make updates to the decades old document.

Constipation med linked to 46 B. cepacia cases in US recalled by PharmaTech

19-Jul-2016 - A constipation medication made by PharmaTech LLC has been recalled after being linked to an outbreak of the bacteria B. cepacia in five US states.

FDA adds 4 API manufacturers to 'Red List'

19-Jul-2016 - Two Chinese and two Indian companies have been banned from importing APIs to the US – one manufacturer says it’s making GMP compliance a “priority.”

News in brief

CDSCO imposes 45 day limit on provision of supplemental data

19-Jul-2016 - Drug manufacturers seeking approval in India now have 45 days to provide the CDSCO with any supplementary information or the application will be rejected.

Ziopharm investigating death in Ph I trial of brain cancer gene therapy

18-Jul-2016 - Ziopharm Oncology has started investigating a death that occured during a Ph I trial of its candidate brain cancer gene therapy, Ad-RTS-hIL-12.


Juno trial restart positive, but CAR-T sector still on a learning curve says TxCell

15-Jul-2016 - The US FDA’s decision to let Juno Therapeutics restart its JCAR015 trial is positive, but the CAR-T sector must learn from safety and efficacy findings says French biotech TxCell.

News in brief

Bayer increases Monsanto offer

14-Jul-2016 - Bayer has continued talks with agri-giant Monsanto over the past several weeks, upping its previous offer to the company.

FDA issues draft guidances on next gen sequencing

14-Jul-2016 - The FDA has issued two new guidances as part of the President’s Precision Medicine Initiative.

DIA 2016

FDA, EMA leaders address barriers, 'big projects,' and Brexit

13-Jul-2016 - Senior leadership from key regulatory bodies gathered at the DIA 2016 Annual Meeting to discuss challenges they face as global regulators, both domestically and as part of international cooperative initiatives.

EMA reviewing several drugs made by Pii in light of MHRA inspection

13-Jul-2016 - The EMA has started assessing some drugs made by Pharmaceutics International Inc (Pii). 

Facing death in the fight against counterfeit medications

11-Jul-2016 - In their pursuit to apply criminology theory to counterfeit medications, Nigerian leaders faced death, says researcher – but the country's efforts have ultimately been successful.

KaloBios CEO on its post-Shkreli 'restart'

11-Jul-2016 - After announcing a new pricing model that promises transparency, affordably, and reasonable return, KaloBios has emerged from bankruptcy – but transparency moving forward will be a shared burden.

Exclusive interview

Regulatory changes 'defining' serialization processes: key considerations and opportunities

11-Jul-2016 - With deadlines around the corner, companies are beginning to plan their serialization initiatives – a process defined by regulatory changes, says Antares Vision.

Drug price cooperation features prominently in Council of EU pharma plan

07-Jul-2016 - The Council of the EU has unveiled a plan to analyse the competitive landscape for pharmaceuticals in Europe in a bid to improve patients' access to medicines.

Shelf life issue halts trial of Scancell's cancer vaccine SCIB1

06-Jul-2016 - UK biopharma company Scancell was forced to halt trials of its flagship cancer immunotherapy SCIB1 because its supplies of the drug no longer meet quality specifications.

Moonshot and independence… A week in the life of the US FDA

30-Jun-2016 - An oncology centre to support the Moonshot Initiative, conflict-of-interest guidance and calls to become independent. Welcome to in-Pharmatechnologist’s US FDA round-up.

“There are units that are doing first-in-human studies that frankly have no business doing them”

DIA: Calls for set standards in Phase I studies following Bial trial tragedy

29-Jun-2016 - Set standards for Phase I trials could stop serious adverse events and patient deaths, says a DIA panellist discussing the recent Bial trial tragedy.

Swissmedic ramps up ad hoc inspections in 2015

28-Jun-2016 - The Swiss drugs regulator saw a near-doubling in the number of inspections prompted by complaints or suspected infringements in 2015, according to its latest annual report.

Brexit: Indian firms worried but Big Pharma and EMA remain positive for now

Worried and bewildered: Brexit sparks uncertainty for Indian pharma in Europe

28-Jun-2016 - Indian companies in the UK are among many in the pharma industry facing an uncertain future after Britain voted to exit the single-market last week.

DIA 2016

'Now is the time to include Japan' says Parexel

24-Jun-2016 - Japan “welcomes innovation” as it makes significant investments in infrastructure and regulatory changes.

UK Biopharma looks to remain strong as Brexit leads to uncharted waters

24-Jun-2016 - The UK biosimilars industry has urged the Government to push for a single marketing authorisation in its upcoming negotiations with the EU, following today’s shock Brexit result.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...